Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1

National Cancer Institute (NCI) on LinkedIn: A new type of

Clinical Trial Results - Cancer Currents Blog - NCI

Frontiers Therapeutic targeting of leukemia stem cells in acute

Pharma Weekly Digest on LinkedIn: #fda #fdaguidance

PDF) Therapeutic targeting of leukemia stem cells in acute myeloid

Edward Carr on LinkedIn: Revumenib Shows Promise for Advanced

I-131 apamistamab induces response among adults with advanced

Therapeutic implications of menin inhibition in acute leukemias

Clinical Trial Results National Cancer Institute

Clinical Trial Results - Cancer Currents Blog - NCI

PDF) Therapeutic targeting of leukemia stem cells in acute myeloid

Treatment - Cancer Currents Blog - NCI

Cancer Currents: An NCI Cancer Research Blog - NCI

Namrata Gautam on LinkedIn: Signals released from dying cancer